
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
This trial is looking at giving atezolizumab with or without tiragolumab after . It is for people:
Having chemotherapy and radiotherapy together is chemoradiotherapy. This is the standard treatment for people with oesophageal cancer that can’t have or don’t want to have surgery.
Atezolizumab is an called a check point inhibitor. It works by blocking a protein that stops the
attacking cancer cells. Doctors already use it for other cancers.
Tiragolumab is another checkpoint inhibitor. It works in the same way as atezolizumab. But it blocks a different protein.
Blocking these proteins could stop the cancer from growing or shrink the cancer.
Researchers think that atezolizumab by itself or in combination with tiragolumab could work well for people with oesophageal cancer. In this trial people will have one of the following after their chemoradiotherapy:
The aims of this trial are to find out:
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if any of these apply. You:
This is an international phase 3 trial. The team need 750 people worldwide to take part with 18 people from the UK.
It is a randomised double blind trial. You go into 1 of 3 treatment groups. Neither you nor your doctor can choose which group you are, or know which group you are in. But if necessary, your doctor can find out which group you are in.
The groups are:
You have 17 cycles of treatment (about 1 year) as long as your cancer doesn’t get any worse.
Research samples
You give tissue samples and blood samples at the start and during the trial. Researchers will use these to look at substances () that might tell them how well the treatment is working.
Some of these samples you must agree to and some you don’t. Your doctor will tell about them.
Quality of life
You fill in a questionnaire:
The questions ask about:
These are quality of life questionnaires.
You see the doctor to have tests before taking part. These tests include:
You see the doctor every 3 weeks while having treatment. This is to see how you are and for bloods.
You have a CT scan or MRI scan:
You stop having scans if your cancer gets worse.
Within a month of finishing treatment you see the doctor for:
Your doctor will then tell you how often they want to see you.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better
Tiragolumab and atezolizumab can affect the immune system. They may cause inflammation in different parts of the body. This can cause serious side effects. These could happen during treatment, or some months after treatment has finished. Rarely, these side effects could be life threatening. |
Tiragolumab is a new drug so there may be side effects we don’t know about. The side effects we know about so far include:
You may have some medication before tiragolumab to reduce the risk of having a reaction to the infusion.
We have information on:
Your doctor or a member of the trial team will talk to you about the side effects of the treatments in this trial before you agree to take part.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Elizabeth Smyth
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.